Trade Ovid Therapeutics Inc. - OVID CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.04 |
Open | 3.13 |
1-Year Change | -12.32% |
Day's Range | 2.98 - 3.13 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 3, 2024 | 3.02 | -0.01 | -0.33% | 3.03 | 3.13 | 2.97 |
May 2, 2024 | 3.04 | 0.04 | 1.33% | 3.00 | 3.07 | 3.00 |
May 1, 2024 | 3.02 | 0.04 | 1.34% | 2.98 | 3.07 | 2.88 |
Apr 30, 2024 | 3.03 | -0.31 | -9.28% | 3.34 | 3.39 | 3.01 |
Apr 29, 2024 | 3.29 | 0.21 | 6.82% | 3.08 | 3.31 | 3.08 |
Apr 26, 2024 | 3.06 | 0.13 | 4.44% | 2.93 | 3.09 | 2.93 |
Apr 25, 2024 | 2.97 | -0.08 | -2.62% | 3.05 | 3.10 | 2.96 |
Apr 24, 2024 | 3.13 | 0.04 | 1.29% | 3.09 | 3.17 | 3.07 |
Apr 23, 2024 | 3.17 | 0.12 | 3.93% | 3.05 | 3.18 | 3.05 |
Apr 22, 2024 | 3.13 | -0.02 | -0.63% | 3.15 | 3.25 | 3.09 |
Apr 19, 2024 | 3.19 | 0.03 | 0.95% | 3.16 | 3.25 | 3.13 |
Apr 18, 2024 | 3.18 | 0.08 | 2.58% | 3.10 | 3.19 | 3.09 |
Apr 17, 2024 | 3.09 | -0.04 | -1.28% | 3.13 | 3.18 | 3.03 |
Apr 16, 2024 | 3.15 | 0.07 | 2.27% | 3.08 | 3.19 | 3.08 |
Apr 15, 2024 | 3.18 | 0.00 | 0.00% | 3.18 | 3.20 | 3.14 |
Apr 12, 2024 | 3.17 | 0.05 | 1.60% | 3.12 | 3.18 | 3.12 |
Apr 11, 2024 | 3.23 | 0.09 | 2.87% | 3.14 | 3.26 | 3.14 |
Apr 10, 2024 | 3.16 | 0.10 | 3.27% | 3.06 | 3.17 | 3.06 |
Apr 9, 2024 | 3.20 | 0.07 | 2.24% | 3.13 | 3.29 | 3.13 |
Apr 8, 2024 | 3.19 | 0.00 | 0.00% | 3.19 | 3.22 | 3.17 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ovid Therapeutics Inc. Company profile
About Ovid Therapeutics Inc
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. The Company's product pipeline includes two late-stage programs and several early-stage programs. The product candidates in its pipeline includes OV935 (soticlestat), OV329, OV882 and OV815. Soticlestat, which is under late-stage program, is for the treatment of dravet syndrome and lennox-gastaut syndrome. OV329, which is under late-stage program, is focused on treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV882, which is under early-stage program, is for the treatment of angelman syndrome and is being developed in collaboration with the University of Connecticut School of Medicine. OV815 is for the treatment of KIF1A Associated Neurological Disorder (KAND) and is being developed in collaboration with Columbia University Irving Medical Center.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ovid Therapeutics Inc revenues increased from $12.6M to $208.4M. Net income applicable to common stockholders totaled $119.8M vs. loss of $81M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development- Balancing decrease of 25% to $45.2M (expense).
Industry: | Bio Therapeutic Drugs |
441 Ninth Avenue, 14Th Floor
NEW YORK
NEW YORK 10001
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com